<?xml version="1.0" encoding="UTF-8"?>
<p>As both lopinavir and ritonavir are CYP3A enzyme inhibitors, multiple drug–drug interactions were described, thus increased attention is recommended when this combination is co-administered with other substances metabolized by the same enzyme. Among the long list of interactions (for the detailed list, visit [
 <xref rid="B80-jcm-09-02084" ref-type="bibr">80</xref>]), we will present several contraindicated drugs to be co-administered with LPV/r in the COVID-19 actual context: dextropropoxyphene, amiodarone, bepril, dofetilide, rifampicin, apixaban, clopidogrel, ticagrelor, St John’s wort, aliskiren, ivabradine, lercanidipine, ranolazine, sildenafil, quetiapine, antivirals such as hepatitis C virus (HCV) DDAs (direct-acting antiviral agents), midazolam, triazolam, cisapride, domperidone, sirolimus, lovastatin, simvastatin, budesonide, fluticasone, mometasone, and triamcinolone [
 <xref rid="B114-jcm-09-02084" ref-type="bibr">114</xref>].
</p>
